Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

BIG Chicago: Uno Studio sul Reddito di Base Garantito per Giovani che Vivono con l'HIV

13 novembre 2026 aggiornato da: University of Chicago

BIG Chicago: Uno Studio sul Reddito di Base Garantito per Giovani Sieropositivi

The goal of this clinical trial is to compare two interventions - Basic Income Guarantee (BIG) + Treatment as Usual and Treatment as Usual among individuals living with HIV who have experienced financial hardships.

The main question it aims to answer is:

Compared with the Treatment as Usual group, will participants in the BIG + Treatment as Usual group be more likely to improve care engagement and viral suppression?

Participants on the study will be:

  • Randomly assigned (like the flip of a coin) to participate in either BIG + Treatment as Usual or Treatment as Usual. Participants will have an equal chance of being placed in either group.
  • Complete 9 surveys over a 36 month period.
  • Complete a release of information so electronic medical record data can be accessed for the 18 months prior to treatment engagement and for 36 months from program enrollment.
  • Participants in the Treatment as Usual group will not receive any intervention.
  • HIV viral load testing will be confirmed at 3 timepoints (baseline, 12 months, and 18 months).
  • Participants in the BIG + Treatment as Usual group will receive $500 monthly income for 18 months.
  • Participants in the BIG + Treatment as Usual group will complete 3 social network surveys to assess how receiving BIG impacts their social networks.
  • A subset of participants in the BIG + Treatment as Usual group (30 participants) will complete 5 individual interviews over the course of receiving BIG and the 18 months after.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

For this randomized controlled trial, the study will recruit, screen, and enroll a total sample of 304 adults aged 18-35 years living with HIV. Participants will be recruited through networks of community-based organizations, HIV care providers, and other community partners. Eligible participants will include individuals who have experienced interruptions in HIV care, defined as being out of HIV care for more than six months within the past 24 months and/or having a detectable HIV viral load (≥200 copies/mL). Eligibility screening and enrollment will be conducted by University of Chicago research staff. Following eligibility confirmation, research staff will explain the scope of the study, the basic income intervention, and participant expectations. All participants will complete informed consent procedures prior to study enrollment. Participants will also complete a release of information authorizing access to electronic medical record data for the purposes of assessing HIV viral load and HIV care engagement throughout the study period.

Randomization and Study Conditions After completion of baseline procedures, participants will be randomized in a 1:1 ratio to either the Basic Income Guarantee (BIG) intervention arm (n=152) or a treatment-as-usual control arm (n=152). Participants randomized to treatment as usual will continue to receive any services and supports they would otherwise access in the community, without receipt of study-provided cash transfers.

Basic Income Guarantee Intervention Participants assigned to the BIG intervention will receive unconditional cash transfers of $500 per month for a total duration of 18 months. Payments will be delivered via reloadable gift cards. The first payment will be issued within the first 10 days of the month following study enrollment and completion of the baseline assessment. No conditions or behavioral requirements are attached to receipt of the cash transfers. All participants, regardless of study arm, will be offered optional financial counseling resources; participation in financial counseling is not required to receive study payments.

Data Collection Procedures Baseline (T1). At enrollment, all participants will complete a baseline survey assessing domains including financial security, employment, housing stability, physical health, mental health, and access to public benefits and social services. Baseline procedures will be completed prior to randomization.

HIV viral load testing. The study will collect HIV viral loads for all participants at baseline and 12 and 18 months. Participants may either: (1) complete a lab blood draw test performed by UChicago testing services staff at the Chicago Center for HIV Elimination (CCHE), or (2) provide study staff with recent test results or documentation of viral load (dated within the prior 30 days of viral load timepoint).

Follow-up Surveys. All participants will complete follow-up surveys every six months for a total of 36 months post-enrollment. Follow-up surveys will reassess baseline domains, including financial security, employment, housing, physical and mental health, and benefit access. Surveys will be administered either remotely or in person using secure data collection platforms.

Social Network Surveys (BIG Arm Only). Participants in the BIG intervention arm will complete a social network survey at baseline, 12 months, and 18 months to examine changes in social ties, support, and resource sharing over the course of the cash transfer period.

Qualitative Interviews (BIG Subsample). A purposive subsample of 30 participants from the BIG intervention arm will participate in longitudinal, in-depth qualitative interviews to explore participants' experiences with the basic income intervention and its perceived impacts. Interviews will occur at baseline and at approximately 9, 18, 27, and 36 months post-enrollment.

Clinical Outcomes All participants will provide authorization for research staff to access electronic medical record data. Primary outcomes will include HIV viral load and HIV care engagement, assessed via medical record abstraction at multiple time points throughout the 36-month study period.

Tipo di studio

Interventistico

Iscrizione (Stimato)

304

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 35 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Living with HIV for 24 months or longer;

  • Ages 18-35;

  • English-speaking;

  • One or both of the following:

    1. Experienced a gap in HIV provider care of 6 or greater months during the prior 12-month period;
    2. Had an unsuppressed viral load at any point within the prior 12-month period (unsuppressed meaning a viral load of 200 copies/mL or higher);
    3. Household income at or below 250% of the Federal Poverty Level; and

Exclusion Criteria:

  • Unwilling/unable to provide informed consent
  • Unable to confirm HIV status
  • Unable to conduct the study in English

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Treatment As Usual

Baseline survey

Participants will go through a baseline survey. Participants will go through a follow-up survey every six months.

Sperimentale: Treatment As Usual plus Basic Income Guaranteed (BIG) Intervention

Baseline survey and BIG intervention

Participants will go through a baseline survey. Participants will go through a follow-up survey every six months. Participants will also receive a $500 monthly income over an 18-month period.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Retention in HIV care
Lasso di tempo: 18 months prior to baseline, to 36 months after baseline

Number of participants who do not experience gaps in care >4 months

18 months prior to baseline, to 36 months after baseline
HIV Viral Suppression
Lasso di tempo: 18 months prior to baseline, to 36 months after baseline

Number of participants with an HIV viral load <200 copies/mL

18 months prior to baseline, to 36 months after baseline

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Jade Pagkas-Bather, University of Chicago

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

29 luglio 2026

Completamento primario (Stimato)

1 luglio 2030

Completamento dello studio (Stimato)

1 luglio 2030

Date di iscrizione allo studio

Primo inviato

25 marzo 2026

Primo inviato che soddisfa i criteri di controllo qualità

25 marzo 2026

Primo Inserito (Effettivo)

31 marzo 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • IRB25-0785
  • 1R01MH140688 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .